U.S. opens tariff probe targeting Germany’s drug pricing policies
U.S. Trade Representative Jamieson Greer said Germany's proposal to reduce spending on medicines was "a serious step backwards."
TL;DR
- The U.S. has initiated an investigation into Germany's drug pricing policies under Section 301 of the Trade Act.
- The investigation is driven by the U.S. claim of "persistent underpayment" for medicines by Germany, which allegedly burdens U.S. commerce.
- Germany is proposing cost-saving measures in its healthcare system, including reduced spending on innovative pharmaceuticals, to control spiraling costs.
- The U.S. argues that American patients are disproportionately funding global pharmaceutical research and development.
- Germany views drug reimbursement as a matter of national jurisdiction and expects the U.S. to respect existing trade agreements.
- The U.S. suggests a potential resolution through constructive negotiations, citing a U.S.-U.K. deal where the U.K. paid higher prices for drugs in exchange for tariff exemptions.
- Critics of U.S. drug pricing policies, like the Most Favored Nation (MFN) policy, argue they can stifle innovation and disincentivize R&D investment.